Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India
Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India
复制标题
DOI：
10.1371/journal.pntd.0007673
复制
发表时间：
2019-08-01
影响因子：
3.8
通讯作者：
Blackwell, Jenefer M.
中科院分区：
文献类型：
--
作者：
Fakiola, Michaela;Singh, Om Prakash;Blackwell, Jenefer M.
两性霉素B为多诺瓦利什曼原虫引起的内脏利什曼病（VL）提供了改进的治疗方法，单剂量脂质体包裹的Ambisome提供了最佳治愈率。根除VL计划的目标是将印度次大陆的发病率降低到
Amphotericin B provides improved therapy for visceral leishmaniasis (VL) caused by Leishmania donovani, with single dose liposomal-encapsulated Ambisome providing the best cure rates. The VL elimination program aims to reduce the incidence rate in the Indian subcontinent to